Consort Medical plc (LON:CSRT) insider Paul Hayes purchased 13 shares of the business’s stock in a transaction on Monday, August 7th. The shares were acquired at an average price of GBX 1,100 ($14.32) per share, for a total transaction of £143 ($186.22).

Paul Hayes also recently made the following trade(s):

  • On Tuesday, June 20th, Paul Hayes bought 4,000 shares of Consort Medical plc stock. The stock was purchased at an average price of GBX 1,094 ($14.25) per share, for a total transaction of £43,760 ($56,986.59).

Consort Medical plc (CSRT) opened at 1093.00 on Thursday. The company has a 50 day moving average price of GBX 1,056.56 and a 200-day moving average price of GBX 1,034.88. The company’s market capitalization is GBX 534.62 million. Consort Medical plc has a one year low of GBX 960.00 and a one year high of GBX 1,180.00.

The company also recently declared a dividend, which will be paid on Friday, October 27th. Investors of record on Thursday, September 21st will be paid a GBX 13.21 ($0.17) dividend. This represents a yield of 1.3%. This is a boost from Consort Medical plc’s previous dividend of $7.09. The ex-dividend date of this dividend is Thursday, September 21st.

TRADEMARK VIOLATION NOTICE: “Consort Medical plc (LON:CSRT) Insider Paul Hayes Acquires 13 Shares” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/10/consort-medical-plc-loncsrt-insider-paul-hayes-acquires-13-shares.html.

A number of equities analysts recently issued reports on the company. Numis Securities Ltd reiterated a “hold” rating and issued a GBX 1,084 ($14.12) target price on shares of Consort Medical plc in a report on Thursday, June 15th. Panmure Gordon reiterated a “buy” rating and issued a GBX 1,145 ($14.91) target price on shares of Consort Medical plc in a report on Thursday, June 15th. Stifel Nicolaus reiterated a “hold” rating and issued a GBX 1,100 ($14.32) target price on shares of Consort Medical plc in a report on Thursday, June 15th. Investec reiterated a “buy” rating and issued a GBX 1,165 ($15.17) target price on shares of Consort Medical plc in a report on Thursday, June 15th. Finally, N+1 Singer reiterated a “buy” rating and issued a GBX 1,125 ($14.65) target price on shares of Consort Medical plc in a report on Thursday, June 15th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of GBX 1,153.17 ($15.02).

Consort Medical plc Company Profile

Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.

Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with MarketBeat.com's FREE daily email newsletter.